A convenient clinical nomogram for predicting the cancer-specific survival of individual patients with small-intestine adenocarcinoma

Na Wang

Department of Clinical Research, The First Affiliated Hospital of Jinan University

Jin Yang

School of Public Health, Xi'an Jiaotong University health science center

Jun Lyu

Department of Clinical Research, The First Affiliated Hospital of Jinan University

Qingqing Liu

School of Public Health, Xi'an Jiaotong University Health Science Center

Hairong He

Clinical Research Center, The First Affiliated Hospital of Xi'an Jiaotong University

Jie Liu

School of Nursing and Health, Henan University

Li Li

School of Nursing and Health, Henan University

Xuequn Ren

Center for Evidence-Based Medicine and Clinical Research, Huaihe Hospital of Henan University

zhendong li (✉ victor7922@163.com)

Department of Hepatobiliary Surgery, The First Affiliated Hospital of Jinan University

Research article

Keywords: small-intestine adenocarcinoma, nomogram, cancer-specific survival

Posted Date: January 17th, 2020

DOI: <https://doi.org/10.21203/rs.2.21096/v1>

License: This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at BMC Cancer on June 1st, 2020. See the published version at <https://doi.org/10.1186/s12885-020-06971-6>.

Abstract

Background: The objective of this study was to develop a practical nomogram for predicting the cancer-specific survival (CSS) of patients with small-intestine adenocarcinoma.

Methods: Patients diagnosed with small-intestine adenocarcinoma between 2010 and 2015 were selected for inclusion in this study from the Surveillance, Epidemiology, and End Results (SEER) database. The selected patients were randomly divided into the training and validation cohorts at a ratio of 7:3. The predictors of CSS were identified by applying both forward and backward stepwise selection methods in a Cox regression model. The performance of the nomogram was measured by the concordance index (C-index), the area under receiver operating characteristic curve (AUC), calibration plots, the net reclassification improvement (NRI), the integrated discrimination improvement (IDI), and decision-curve analysis (DCA).

Results: Multivariate Cox regression indicated that factors including age at diagnosis, sex, marital status, insurance status, histology grade, SEER stage, surgery status, T stage, and N stage were independent covariates associated with CSS. These factors were used to construct a predictive model, which was built and virtualized by a nomogram. The C-index of the constructed nomogram was 0.858. The AUC values indicated that the established nomogram displayed better discrimination performance than did the seventh edition of the American Joint Committee on Cancer TNM staging system in predicting CSS. The IDI and NRI also showed that the nomogram exhibited superior performance in both the training and validation cohorts. Furthermore, the calibrated nomogram predicted survival rates that closely corresponded to actual survival rates, while the DCA demonstrated the considerable clinical usefulness of the nomogram.

Conclusion: We have constructed a nomogram for predicting the CSS of small-intestine adenocarcinoma patients. This prognostic model may improve the ability of clinicians to predict survival in individual patients and provide them with treatment recommendations.

Background

The small intestine consists of the duodenum, jejunum, and ileum. It is the longest part of the digestive tract and the main location where food digestion and absorption occur. Its absorption area accounts for 99% of the total mucosal area of the digestive tract [1]. Malignancies in the small intestine are relatively rare in clinical practice, accounting for less than 5% of all malignant tumors of the digestive tract [2, 3]. Adenocarcinoma, neuroendocrine tumors, stromal tumors, and lymphoma are the four main histological types of small-intestine malignancies, of which small-intestine adenocarcinoma is the most-common type, accounting for 30–40% of these tumors [4, 5]. The rarity of small-intestine adenocarcinoma restricts studies of its treatment and prognosis. Moreover, because the small intestine is located near the large intestine, small-intestine adenocarcinoma is generally considered to be similar to colorectal adenocarcinoma, and some of the applied treatments are therefore based on colorectal cancer [6]. There

has been far less research into the prognosis of small-intestine adenocarcinoma compared to colorectal cancer.

The most commonly used small-intestine adenocarcinoma prediction system is the American Joint Committee on Cancer (AJCC) TNM staging system, which is based on the tumor infiltration depth (T), number of metastatic lymph nodes (N), and distant metastasis (M). Although the TNM system is widely used to estimate prognoses and determine clinical treatments of cancer patients, this system might not adequately encompass the tumor biology and therefore be unreliable for predicting outcomes of small-intestine adenocarcinoma [7]. Furthermore, other clinicopathological features such as age of diagnosis, marriage status, tumor location, and surgery status also affect the prognosis [8–10].

Nomograms have been widely used as a valuable pictorial tool for combining biological and clinical variables in the construction of prognostic models using traditional statistical methods such as a Cox proportional-hazards regression model to determine the prognosis of multiple malignancies [11–13]. In addition, several studies have shown that a nomogram is superior to the AJCC TNM staging system in predicting the survival of cancer patients [14–17]. However, few studies have used nomograms to predict the prognosis of patients with small-intestine adenocarcinoma. This study therefore aimed to construct a clinical nomogram for predicting the 3- and 5-year cancer-specific survival (CSS) in small-intestine adenocarcinoma patients based on a cohort from the Surveillance, Epidemiology, and End Results (SEER) database.

Methods

Study cohorts

The SEER database covers approximately 28% of the US population and contains a large amount of evidence-based medical data [18]. We selected cases of small-intestine adenocarcinoma using the newest database of SEER* Stat (version 8.3.5; <https://seer.cancer.gov/>): 'Incidence–SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2017 Sub (1973–2015 varying)'. The patients were identified using the following SEER variables: "Site Recode ICD-O-3 / WHO 2008 classification" (small intestine) and "Histology recode – broad groupings" (histology codes: 8140–8389). The TNM staging data were extracted according to the code 'derived AJCC TNM stage group 7th ed' (henceforth simply referred to as the AJCC staging system); this was published in 2010, and so the allowable year of diagnosis ranged from 2010 to 2015. Survival information was extracted using the codes 'SEER cause-specific death classification' and 'survival months'. Patients were excluded if their first primary tumor was not small-intestine adenocarcinoma, were younger than 18 years, or their information was unknown or ambiguous.

Our screening of the SEER database identified 4971 eligible patients. Random numbers generated using R software were used to randomly allocate 70% (n = 3479) of these patients to a training cohort for developing the nomogram, with the remaining 30% (n = 1492) of the patients used as a validation cohort.

This study was conducted in accordance with the SEER data-use agreement, and was approved by the institutional research committee of the First Affiliated Hospital of Xi'an Jiaotong University.

Study variables and endpoint

The characteristics of the patients analyzed were age at diagnosis, sex, race, marital status, insurance status, histology grade, AJCC stage, SEER stage, T stage, N stage, M stage, treatment status (for surgery, chemotherapy, and radiotherapy), and survival time. The marital status was dichotomized into married (including domestic partnership and common-law marriage) and unmarried (including single, separated, divorced, or widowed). The primary endpoint was the CSS time, which was defined as the period from the date of diagnosis to the date of death attributed to small-intestine adenocarcinoma.

Statistical analyses

Continuous variables that conformed to the normal distribution are expressed as mean $\pm$ SD (standard deviation) values, while other continuous variables are expressed as median values with 25th and 75th percentiles, and categorical variables are presented as numbers with percentages. The independent prognostic variables for small-intestine adenocarcinoma determined by applying both forward and backward stepwise selection methods in a Cox regression model were used to construct the nomogram for predicting the 3- and 5-year CSS.

The performance of the nomogram was measured based on the concordance index (C-index) and assessed by calibration curves. The C-index reflects the predictive ability between observed and predicted outcomes, with a higher C-index indicating a better ability to separate patients with different survival outcomes. The calibration curve was used to determine whether the predicted and observed survival probabilities were consistent with 1000 bootstrapped resamples.

The area under the receiver operating characteristic (ROC) curve (AUC) was used to assess and compare the precision of the 3- and 5-year CSS rates predicted by the nomogram. We determined the improvement that the new prediction model represented over the AJCC staging system in both the training and validation cohorts using the net reclassification improvement (NRI) and the integrated discrimination improvement (IDI). Finally, we used decision-curve analysis (DCA) to test the clinical applicability of the predictive model. A two-sided probability value of $P \leq 0.05$ was considered to be statistically significant. All analyses were performed using R software (version 3.5.1; <http://www.r-project.org>).

Results

Patient characteristics

The baseline characteristics of the included patients are presented in Table 1. The median age at diagnosis was 63 years (25th–75th percentiles 54–72 years), and most of the patients were male, white, married, and insured. The most-common tumor grade was well-differentiated ($n = 2962$, 59.6%), while stage III ($n = 2108$, 42.4%) was the most common AJCC stage. Localized, regional, and distant tumors

were present in 32.4%, 43.7%, and 23.9% of the patients, respectively. Most patients were categorized as TNM stages T3 (n = 1898, 38.2%), N1 (n = 2592, 52.1%), and M0 (n = 3861, 77.7%). There were 4525 (91.0%), 111 (2.2%), and 897 (18.0%) patients who received surgery, radiotherapy, and chemotherapy, respectively.

Nomogram construction

The following nine independent prognostic variables were found to be associated with CSS after performing both forward and backward stepwise selection in the Cox regression model in the training cohort: age at diagnosis, sex, marital status, insurance status, histology grade, SEER stage, surgery status, T stage, and N stage (Table 2). The nomogram established for predicting the 3- and 5-year CSS included variables that were significantly associated with CSS in the training cohort. It is easy to see from the nomogram in Fig. 1 that age at diagnosis is the greatest contributor to the prognosis, followed by histology grade, surgery status, SEER stage, T stage, N stage, insurance status, sex, and marital status. The survival probability of an individual patient can be easily calculated by adding their scores for all of the selected variables.

Validation and calibration of the nomogram

The C-index values of the nomogram and AJCC staging system for CSS in the training cohort were 0.858 and 0.643, respectively. Compared with the AJCC staging system, the nomogram showed enhanced discrimination for CSS prediction in the training cohort. Significant differences in C-index values for CSS were also found in the validation cohort, being 0.861 for the nomogram and 0.613 for the AJCC staging system.

The two AUC models of the 3- and 5-year CSS rates regarding the prediction ability of the two data sets were compared (Fig. 2). For the training cohort, the AUCs for predicting the 3- and 5-year CSS rates were 0.873 and 0.854, respectively, for the nomogram, and 0.653 and 0.654 for the AJCC staging system; the corresponding values in the validation cohort were 0.893, 0.865, 0.601, and 0.611, respectively. Figure 2 shows that the nomogram exhibited superior survival predictive ability compared to the AJCC staging system. Calibration plots of the nomogram show that the predicted 3- and 5-year survival probabilities for the training and validation cohorts were almost identical to the actual observations, especially for the 3-year CSS (Fig. 3).

The NRI values for the 3- and 5-year CSS rates were 101.4 (95% CI = 89.4–110.9%) and 90.7% (95% CI = 79.0–106.3%), respectively, in the training cohort, and 113.1% (95% CI = 99.4–125.5%) and 95.1% (95% CI = 76.2–108.4%) in the validation cohort. These results indicate the significant superiority of the predictive performance of the nomogram. Similarly, the IDI values for the 3- and 5-year CSS rates were 30.1% and 32.6%, respectively, in the training cohort, and 34.2% and 35.4% in the validation cohort (all $P < 0.001$). These results further demonstrate the improved predictive performance of the nomogram.

Finally, DCA was used to compare the clinical validity of the nomogram to that of the AJCC staging system. A plot of the 3- and 5-year DCA curves with the threshold probability as the abscissa and the net benefit as the ordinate graphically indicate that compared with the AJCC staging system, the nomogram showed a larger net benefit across the range of death risks both in the training and validation cohorts (Fig. 4).

Discussion

Small-intestine adenocarcinoma is a rare tumor that has a very low incidence compared with colorectal cancer. The smallness of the available samples associated with this rarity restricts data analyses and the ability to draw generalized conclusions in studies of small-intestine adenocarcinoma, which means that the relevant prognosis factors are still controversial [19, 20]. Nomograms have been widely used in recent years for predicting individualized survival outcomes in cancer patients [21–25]. The rarity of small-intestine adenocarcinoma increases the practicality of using a brief nomogram to predict patient survival in clinical decision-making.

Prognostic factors closely associated with CSS in small-intestine adenocarcinoma were included in the construction of the present nomogram, which was used to predict the 1- and 3-year CSS for small-intestine adenocarcinoma. Compared with the AJCC staging system, the nomogram shows better predictive performance, with a C-index of 0.858. Furthermore, the ROC curve, NRI, and IDI also demonstrated that the nomogram showed better predictive ability than the AJCC staging system. Moreover, the calibration curves indicated that the predicted 3- and 5-year CSS rates for the training and validation cohorts were almost identical to the actual observations, especially for the 3-year CSS. Finally, the DCA curves showed that the nomogram exhibits better clinical usefulness for predicting survival compared to the AJCC staging system.

The proposed nomogram contains several independent prognostic factors—age at diagnosis, sex, marital status, insurance status, histology grade, SEER stage, surgery status, T stage, and N stage—that were selected by applying both forward and backward stepwise selection methods in a Cox regression model. We found that increasing age was associated with worse survival outcomes, which is consistent with previous findings [6]. Some studies have suggested that small-intestine adenocarcinoma is more prevalent in males than in females [26]. We similarly found that the proportion of male patients in our study cohort was higher than that of females (52.2% vs 47.7%), and that being female appeared to be a protective factor for the CSS of small-intestine adenocarcinoma. It is worth noting that, unlike most previous studies, we included insurance status in our analysis, and found that Medicaid patients had an increased risk of death compared to insured patients; subsequent research is necessary to explain this finding.

Surgery remains the most commonly used treatment method for small-intestine adenocarcinoma [27, 28], and it has been shown that palliative chemotherapy and radiation can also play a role in improving survival outcomes in these patients [4, 29, 30]. However, our research did not find this association, the

main reason being that the current data on radiotherapy and chemotherapy in the SEER database have potential bias because many factors that influence the course of treatment are not captured in the registry data.

Our nomogram highlights the significant contribution of histology grade, which is consistent with previous studies showing that histology grade is an independent predictor of survival [10, 31, 32]. In addition, there was no definitive correlation between tumor differentiation and tumor size or lymph node metastasis, while the latter two are important components of the TNM staging system. Even two patients at the same TNM stage can exhibit different scores for CSS on our nomogram based on their degrees of tumor differentiation. This may also be the reason why the survival predictions of our nomogram are superior to using the AJCC staging system.

Besides the factors mentioned above, distant metastasis and increased tumor and lymph node metastasis are risk factors for survival in small-intestine adenocarcinoma, as found previously [10, 32–34]. Moreover, our study also showed that not being married is associated with a poor prognosis of small-intestine adenocarcinoma, which is consistent with the findings of Chen et al. [35].

This study was subject to several limitations. First, although 14 variables were involved, only 9 of them are included in the nomogram, and there are also many other variables such as comorbidities, chemotherapy drugs, and molecular factors not included in the SEER database that might affect patient survival. Second, although we randomly divided the patients into the training and validation cohorts (at a ratio of 7:3) to evaluate the nomogram both internally and externally, it remains necessary to assess the accuracy of the model based on external validation in other populations. Third, the SEER database is retrospective and we excluded patients with incomplete information, which may have led to selection bias. Finally, although the DCA demonstrated the superiority of our nomogram over the AJCC staging system with a greater net benefit, this analysis is not absolutely accurate and so should only be used as reference information in clinical decision-making.

Conclusion

In conclusion, we have developed and validated a nomogram for predicting the 3- and 5-years CSS rates of small-intestine adenocarcinoma patients. The nomogram is brief and convenient, and it exhibited a superior survival predictive ability compared to the AJCC staging system. The nomogram might assist clinicians in making predictions about the survival of individual patients and provide improved treatment recommendations.

Abbreviations

CSS:cancer-specific survival; SEER:Surveillance, Epidemiology, and End Results; C-index:concordance index; ROC:receiver operating characteristic; AUC:area under receiver operating characteristic curve; NRI:net reclassification improvement; IDI:integrated discrimination improvement; DCA:decision-curve

analysis; AJCC:American Joint Committee on Cancer; SD:standard deviation; HR:hazard ratio; CI:confidence interval.

Declarations

Acknowledgements

The authors would like to thank SEER for open access to the database.

Availability of data and materials

The data were abstracted from the Surveillance, Epidemiology, and End Results (SEER) database. This is an open database. (<https://seer.cancer.gov>).

Authors' contributions

NW, JY and ZL designed the study. QL and HH collected and analyzed the data. NW, JLi and LL organized the manuscript. JY, ZL, JLy and XR reviewed the papers and revised the manuscript. All the authors (NW, JY, JLy, QL, HH, JLi, LL, XR and ZL) have read and approved the final manuscript. All authors contributed toward data analysis, drafting and revising the paper and agree to be accountable for all aspects of the work.

Funding

This study was supported by the National Social Science Foundation of China (No.16BGL183), the Clinical Research Award of the First Affiliated Hospital of Xi'an Jiaotong University of China (No. XJTU1AF-CRF-2016-024).

Ethics approval and consent to participate

This study was approved by the institutional research committee of the First Affiliated Hospital of Jinan University.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

References

1. Raghav K, Overman MJ: Small bowel adenocarcinomas—existing evidence and evolving paradigms. *Nat Rev Clin Oncol* 2013, 10(9):534-544.

2. Makino S, Takahashi H, Haraguchi N, Nishimura J, Hata T, Matsuda C, Ikenaga M, Murata K, Yamamoto H, Doki Y *et al*: A Single Institutional Analysis of Systemic Therapy for Unresectable or Recurrent Small Bowel Adenocarcinoma. *Anticancer Res* 2017, 37(3):1495-1500.
3. Siegel RL, Fedewa SA, Miller KD, Goding-Sauer A, Pinheiro PS, Martinez-Tyson D, Jemal A: Cancer statistics for Hispanics/Latinos, 2015. *CA Cancer J Clin* 2015, 65(6):457-480.
4. Aparicio T, Zaanani A, Mary F, Afchain P, Manfredi S, Evans TR: Small Bowel Adenocarcinoma. *Gastroenterol Clin North Am* 2016, 45(3):447-457.
5. Williamson JM, Williamson RC: Small bowel tumors: pathology and management. *J Med Assoc Thai* 2014, 97(1):126-137.
6. Young JJ, Mongoue-Tchokote S, Wieghard N, Mori M, Vaccaro GM, Sheppard BC, Tsikitis VL: Treatment and Survival of Small-bowel Adenocarcinoma in the United States: A Comparison With Colon Cancer. *Dis Colon Rectum* 2016, 59(4):306-315.
7. Nicholl MB, Ahuja V, Conway WC, Vu VD, Sim MS, Singh G: Small bowel adenocarcinoma: understaged and undertreated? *Ann Surg Oncol* 2010, 17(10):2728-2732.
8. Zhang S, Yuan W, Zhang J, Chen Y, Zheng C, Ma J, Jiang Q, Zhao Y, Xu Q, Wang C: Clinicopathological features, surgical treatments, and survival outcomes of patients with small bowel adenocarcinoma. *Medicine (Baltimore)* 2017, 96(31):e7713.
9. Chen Z, Cui J, Dai W, Yang H, He Y, Song X: Influence of marital status on small intestinal adenocarcinoma survival: an analysis of the Surveillance, Epidemiology, and End Results (SEER) database. *Cancer Manag Res* 2018, 10:5667-5676.
10. Tran TB, Qadan M, Dua MM, Norton JA, Poultides GA, Visser BC: Prognostic relevance of lymph node ratio and total lymph node count for small bowel adenocarcinoma. *Surgery* 2015, 158(2):486-493.
11. Lin Z, Yan S, Zhang J, Pan Q: A Nomogram for Distinction and Potential Prediction of Liver Metastasis in Breast Cancer Patients. *J Cancer* 2018, 9(12):2098-2106.
12. Chen G, Yu H, Wang Y, Li C, Zhou M, Yu Z, Zheng X, Wu X, Shan Y, Zhang Q *et al*: A novel nomogram for the prediction of intrahepatic cholangiocarcinoma in patients with intrahepatic lithiasis complicated by imagiologically diagnosed mass. *Cancer Manag Res* 2018, 10:847-856.
13. Balachandran VP, Gonen M, Smith JJ, DeMatteo RP: Nomograms in oncology: more than meets the eye. *Lancet Oncol* 2015, 16(4):e173-e180.
14. Sternberg CN: Are nomograms better than currently available stage groupings for bladder cancer? *J Clin Oncol* 2006, 24(24):3819-3820.
15. Iasonos A, Schrag D, Raj GV, Panageas KS: How to build and interpret a nomogram for cancer prognosis. *J Clin Oncol* 2008, 26(8):1364-1370.
16. Chen S, Lai Y, He Z, Li J, He X, Shen R, Ding Q, Chen H, Peng S, Liu W: Establishment and validation of a predictive nomogram model for non-small cell lung cancer patients with chronic hepatitis B viral infection. *J Transl Med* 2018, 16(1):116.

17. Roberto M, Botticelli A, Strigari L, Ghidini M, Onesti CE, Ratti M, Benzoni I, Pizzo C, Falcone R, Lomiento D *et al*: Prognosis of elderly gastric cancer patients after surgery: a nomogram to predict survival. *Med Oncol* 2018, 35(7):111.
18. Zeng C, Wen W, Morgans AK, Pao W, Shu XO, Zheng W: Disparities by Race, Age, and Sex in the Improvement of Survival for Major Cancers: Results From the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program in the United States, 1990 to 2010. *Jama Oncol* 2015, 1(1):88-96.
19. Haselkorn T, Whittemore AS, Lilienfeld DE: Incidence of small bowel cancer in the United States and worldwide: geographic, temporal, and racial differences. *Cancer Causes Control* 2005, 16(7):781-787.
20. Lu Y, Frobom R, Lagergren J: Incidence patterns of small bowel cancer in a population-based study in Sweden: increase in duodenal adenocarcinoma. *Cancer Epidemiol* 2012, 36(3):e158-e163.
21. Tang X, Zhou X, Li Y, Tian X, Wang Y, Huang M, Ren L, Zhou L, Ding Z, Zhu J *et al*: A Novel Nomogram and Risk Classification System Predicting the Cancer-Specific Survival of Patients with Initially Diagnosed Metastatic Esophageal Cancer: A SEER-Based Study. *Ann Surg Oncol* 2019, 26(2):321-328.
22. Guo L, Jiang L, Gong Y, Zhang H, Li X, He M, Sun W, Ling H, Hu X: Development and validation of nomograms for predicting overall and breast cancer-specific survival among patients with triple-negative breast cancer. 2018, Volume 10:5881-5894.
23. Dai D, Jin H, Wang X: Nomogram for predicting survival in triple-negative breast cancer patients with histology of infiltrating duct carcinoma: a population-based study. *Am J Cancer Res* 2018, 8(8):1576-1585.
24. Wu Q, Wang W, Huang Y, Fang S, Guan Y: Nomograms for estimating survival in patients with liver-only colorectal metastases: A retrospective study. *Int J Surg* 2018, 60:1-8.
25. Jiang S, Zhao R, Li Y, Han X, Liu Z, Ge W, Dong Y, Han W: Prognosis and nomogram for predicting postoperative survival of duodenal adenocarcinoma: A retrospective study in China and the SEER database. *Sci Rep* 2018, 8(1):7940.
26. Goodman MT, Matsuno RK, Shvetsov YB: Racial and ethnic variation in the incidence of small-bowel cancer subtypes in the United States, 1995-2008. *Dis Colon Rectum* 2013, 56(4):441-448.
27. Saxena A, Valle SJ, Liauw W, Morris DL: Recurrence and Survival Outcomes After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Small Bowel Adenocarcinoma. *Anticancer Res* 2017, 37(10):5737-5742.
28. Aparicio T, Zaanani A, Mary F, Afchain P, Manfredi S, Evans TR: Small Bowel Adenocarcinoma. *Gastroenterol Clin North Am* 2016, 45(3):447-457.
29. Koo DH, Yun S, Hong YS, Ryu M, Lee J, Chang H, Ryoo B, Kang Y, Kim TW: Systemic chemotherapy for treatment of advanced small bowel adenocarcinoma with prognostic factor analysis: retrospective study. *Bmc Cancer* 2011, 11(1):205.
30. Fadavi P, Zare M: Adenocarcinoma of Small Bowel. *Rare Tumors* 2015, 7(2):5517.

31. Fang C, Wang W, Feng X, Sun J, Zhang Y, Zeng Y, Wang J, Chen H, Cai M, Lin J *et al*: Nomogram individually predicts the overall survival of patients with gastroenteropancreatic neuroendocrine neoplasms. *Br J Cancer* 2017, 117(10):1544-1550.

32. Overman MJ, Hu C, Wolff RA, Chang GJ: Prognostic value of lymph node evaluation in small bowel adenocarcinoma. *Cancer-Am Cancer Soc* 2010, 116(23):5374-5382.

33. Chang HK, Yu E, Kim J, Bae YK, Jang KT, Jung ES, Yoon GS, Kim JM, Oh YH, Bae HI *et al*: Adenocarcinoma of the small intestine: a multi-institutional study of 197 surgically resected cases. *Hum Pathol* 2010, 41(8):1087-1096.

34. McLaughlin PD, Maher MM: Primary malignant diseases of the small intestine. *AJR Am J Roentgenol* 2013, 201(1):W9-W14.

35. Influence of marital status on small intestinal adenocarcinoma survival: an analysis of the Surveillance, Epidemiology, and End Results (SEER) database.

Tables

Table1. Patient characteristics in the study

Variable	Training Cohort (n=3479)	Validation Cohort (n=1492)	Total (n=4971)
Age, median (25th–75th percentile)	63(54-72)	63(54-72)	63(54-72)
Sex n (%)			
Male	1806 (51.9)	791(53.0)	2597 (52.2)
Female	1673(48.1)	701 (47.0)	2374 (47.7)
Race n (%)			
White	2751 (79.2)	1173 (78.6)	3929 (79.0)
Black	574 (16.5)	250 (16.7)	824 (16.6)
Other	149 (4.3)	69 (4.6)	218 (4.4)
Marital status n (%)			
Married	2192 (63.0)	943 (63.2)	3135 (63.1)
Unmarried	1287 (37.0)	549 (36.8)	1836 (36.9)
Grade n (%)			
I	2080 (59.8)	882 (59.1)	2962 (59.6)
II	1000 (28.7)	412 (27.6)	1412 (28.4)
III	374 (10.7)	191 (12.8)	565 (11.4)
IV	25 (0.7)	7 (0.5)	32 (0.6)
AJCC TNM stage n (%)			
I	541 (15.5)	188 (12.6)	729 (14.7)
II	707 (20.0)	317 (21.2)	1024 (20.6)
III	1459 (41.9)	649 (43.5)	2108 (42.4)
IV	772 (22.2)	338 (22.6)	1110 (22.3)
SEER Stage n (%)			
Localized	1142 (32.8)	468 (31.3)	1610 (32.4)
Regional	1514 (43.5)	660 (44.2)	2174 (43.7)
Distant	823 (23.6)	364 (24.4)	1187 (23.9)
Insurance Status			
Insured	3038 (87.3)	1282 (85.9)	4320 (86.9)
Medicaid	341 (9.8)	156 (10.4)	497 (10.0)

Uninsured	100 (2.9)	54 (3.6)	154 (3.1)
T stage			
T1	627 (18.0)	221 (14.8)	848 (17.1)
T2	554 (15.9)	252 (16.9)	806 (16.2)
T3	1333 (38.3)	565 (37.8)	1898 (38.2)
T4	965 (27.7)	454 (30.4)	1419 (28.5)
N stage			
N0	1516 (43.6)	625 (41.9)	2141 (43.1)
N1	1806 (51.9)	786 (52.6)	2592 (52.1)
N2	157 (4.5)	81 (5.4)	238 (4.8)
M stage			
M0	2707 (77.8)	1154 (77.3)	3861 (77.7)
M1	772 (22.2)	338 (22.6)	1110 (22.3)
Surgery			
Yes	3155 (90.7)	1370 (91.8)	4525 (91.0)
No	324 (9.3)	122 (8.2)	446 (9.0)
Radiation			
Yes	80 (2.3)	31 (2.1)	111 (2.2)
No	3399 (97.7)	1461 (97.9)	4860 (97.7)
Chemotherapy			
Yes	618 (17.8)	279 (18.7)	897 (18.0)
No	2861 (82.2)	1213 (81.2)	4074 (81.9)

Table2. Selected variables by multivariate Cox regression analysis

characteristic	Multivariate analysis		
	HR	95%CI	<i>P</i>
Age	1.035	1.027-1.042	<0.001
Sex			
Male	Reference		
Female	0.745	0.627-0.885	<0.001
Marital status			
Married	Reference		
Unmarried	1.333	1.118-1.589	0.001
Grade			
I	Reference		
II	4.325	3.458-5.410	<0.001
III	7.641	5.963-9.791	<0.001
IV	7.883	3.973-15.641	<0.001
SEER stage			
Localized	Reference		
Regional	1.422	1.049-1.928	0.023
Distant	2.884	2.153-3.864	<0.001
Insurance			
Insured	Reference		
Medicaid	1.364	1.047-1.777	0.022
Uninsured	1.284	0.818-2.017	0.277
Surgery			
Yes	Reference		
No	4.301	3.455-5.355	<0.001
T stage			
T1	Reference		
T2	0.540	0.357-0.817	0.004
T3	0.956	0.710-1.286	0.764
T4	1.336	0.100-1.786	0.050

N stage			
N0	Reference		
N1	0.884	0.708-1.103	0.273
N2	1.776	1.343-2.350	<0.001

HR: hazard ratio; CI: confidence interval.

Figures

Figure 1

Nomogram predicting the 3- and 5-year cancer-specific survival (CSS) rates of patients with small-intestine adenocarcinoma. The nomogram summed the points identified on the scale for each variable. The total points projected on the bottom scales indicate the probabilities of 3- and 5-year CSS.

Figure 2

Comparison of the AUCs of the nomogram and 7th AJCC TNM staging system. Area under the curves of the two models to predict cancer-specific survival (CSS) at 3 years (A) and 5 years (B) using the training set as well as at 3 years (C) and 5 years (D) using the validation set.

Figure 3

The calibration of the nomograms using the training set and validation set. (A) 3-year cancer-specific survival (CSS) and (B) 5-year CSS according to the training set. (C) 3-year CSS and (D) 5-year CSS according to the training set.

Figure 4

Decision curve analysis. In the figure, the abscissa is the threshold probability, the ordinate is the net benefit rate. The horizontal one indicates that all samples are negative and all are not treated, with a net benefit of zero. The oblique one indicates that all samples are positive. The net benefit is a backlash with a negative slope. A and B came from the training set, and C and D came from the validation set.